Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).

IF 1.1 Q2 MEDICINE, GENERAL & INTERNAL

Wiener medizinische Wochenschrift Pub Date : 2025-03-05 DOI:10.1007/s10354-025-01072-0

Magdalena Grass, Klaus Geissler

{"title":"Features of TP53-mutated patients with chronic myelomonocytic leukemia in a national (ABCMML) and international cohort (cBIOPORTAL).","authors":"Magdalena Grass, Klaus Geissler","doi":"10.1007/s10354-025-01072-0","DOIUrl":null,"url":null,"abstract":"<p><p>Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of TP53-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; n = 322) and in the international platform cBIOPORTAL (n = 399). The prevalences of TP53 mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in TP53-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with TP53 mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.</p>","PeriodicalId":23882,"journal":{"name":"Wiener medizinische Wochenschrift","volume":" ","pages":""},"PeriodicalIF":1.1000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Wiener medizinische Wochenschrift","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s10354-025-01072-0","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, GENERAL & INTERNAL","Score":null,"Total":0}

引用次数: 0

Abstract

Big data collected in large international cooperations allow validation of findings from traditional national patient cohorts for proving consistency. In this study we analyzed outcomes and phenotypic features of TP53-mutated chronic myelomonocytic leukemia (CMML) patients in the Austrian biodatabase for CMML (ABCMML; n = 322) and in the international platform cBIOPORTAL (n = 399). The prevalences of TP53 mutations were 1.58 and 3.66, respectively. Numerically, overall survival was shorter in TP53-mutated patients in both cohorts (ABCMML 10.0 vs. 30.0 months and cBIOPORTAL 8.9 vs. 34.5 months), but this was statistically significant only in the cBIOPORTAL cohort. Decreased hemoglobin values and the presence of blast cells in peripheral blood were significantly associated with TP53 mutations in the cBIOPORTAL group but not in the ABCMML database. Our study indicates the necessity of sufficient patient numbers for the comparison of CMML patients regarding outcome and phenotype according to their molecular subtype, particularly in the case of rare mutations.

查看原文本刊更多论文

国家（ABCMML）和国际队列（cBIOPORTAL）中tp53突变的慢性髓单细胞白血病患者的特征

在大型国际合作中收集的大数据可以验证来自传统国家患者队列的发现，以证明一致性。在这项研究中，我们分析了奥地利CMML生物数据库中tp53突变的慢性髓细胞白血病（CMML）患者的结局和表型特征。n = 322)和国际平台cBIOPORTAL （n = 399）。TP53突变的患病率分别为1.58和3.66。数值上，两个队列中tp53突变患者的总生存期较短（ABCMML 10.0个月vs 30.0个月，cBIOPORTAL 8.9个月vs 34.5个月），但这仅在cBIOPORTAL队列中具有统计学意义。在cBIOPORTAL组中，血红蛋白值的降低和外周血中母细胞的存在与TP53突变显著相关，但在ABCMML数据库中没有。我们的研究表明，有必要根据分子亚型对CMML患者的预后和表型进行足够的患者数量的比较，特别是在罕见突变的情况下。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Wiener medizinische Wochenschrift MEDICINE, GENERAL & INTERNAL-

CiteScore

2.50

自引率

0.00%

发文量

期刊介绍： ''From the microscope to clinical application!'', Scientists from all European countries make available their recent research results and practical experience through Wiener Medizinische Wochenschrift, the renowned English- and German-language forum. Both original articles and reviews on a broad spectrum of clinical and preclinical medicine are presented within the successful framework of thematic issues compiled by guest editors. Selected cutting-edge topics, such as dementia, geriatric oncology, Helicobacter pylori and phytomedicine make the journal a mandatory source of information.